Ipsen is buying Kartos Therapeutics to get navtemadlin, which has reached Part 3 testing within the blood most cancers myelofibrosis. The Kartos oral small molecule takes a novel method to restoring the operate of p53, a tumor-suppressing protein.
The put up Ipsen’s $450M Deal Brings Drug That Might Make a Customary Blood Most cancers Remedy Higher appeared first on MedCity Information.
